Novartis Fluad Phase III study meets primary endpoint
The Phase III randomised, blinded, controlled study was conducted at trial sites in Germany and Finland. Novartis said that the study aimed to assess the reactogenicity of the
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.
Shrink said that Stemage software will be launched with StemDisc products for developing intuitive and integrated bio-informatics database to facilitate the acquisition and sharing of three-dimensional (3D) imaging